Skip to main
ACOG

ACOG Stock Forecast & Price Target

ACOG Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alpha Cognition Inc., a biopharmaceutical firm focusing on neurodegenerative disease treatments, particularly Alzheimer's, is expected to see significant sales growth as their contracting strategies are implemented, with substantial acceleration anticipated in 2026. The company's proactive approach includes building a dedicated commercial team to differentiate ZUNVEYL from existing treatments and explore additional licensing opportunities. Furthermore, with an expected year-end 2025 cash balance of approximately $63 million, Alpha Cognition appears well-positioned to sustain operations and reach profitability in the near to medium term.

Bears say

Alpha Cognition's full-year 2025 net sales forecast has been reduced to $5.7 million from a previous estimate of $11.7 million, reflecting expectations of slower contracting and reimbursement processes. Key risks for the company include potential delays in the launch of its lead product, ZUNVEYL, as well as challenges related to market uptake due to pricing pressures and increased competition from both generic and branded drugs. Additionally, there are concerns about possible setbacks in clinical development and the risk of medium- to long-term dilution, which contributes to an overall negative outlook for the stock.

ACOG has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alpha Cognition Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alpha Cognition Inc (ACOG) Forecast

Analysts have given ACOG a Strong Buy based on their latest research and market trends.

According to 1 analysts, ACOG has a Strong Buy consensus rating as of Mar 31, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alpha Cognition Inc (ACOG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.